Iressa Cross-Over Study Could Show Clinical Benefit, AZ Says; ODAC Is Wary
Executive Summary
AstraZeneca believes a controlled, cross-over trial could be used to confirm the sympom benefit of Iressa in refractory non-small cell lung cancer patients, VP-Medical Director of Oncology George Blackledge, MD, said during FDA's Oncologic Drugs Advisory Committee Sept. 24
You may also be interested in...
AstraZeneca Iressa Response Working, Company Says: Docs Move To Tarceva
AstraZeneca's efforts to promote Genentech/OSI's Tarceva as the first-choice epidermal growth factor receptor therapy are working, the company told FDA's Oncologic Drugs Advisory Committee March 4
AstraZeneca Iressa Response Working, Company Says: Docs Move To Tarceva
AstraZeneca's efforts to promote Genentech/OSI's Tarceva as the first-choice epidermal growth factor receptor therapy are working, the company told FDA's Oncologic Drugs Advisory Committee March 4
Iressa Committee Will Not Vote On Market Withdrawal; FDA To Review Data
FDA's Oncologic Drugs Advisory Committee will not vote on whether the lung cancer therapy Iressa should be removed from the market during its March 4 meeting, AstraZeneca said